Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (1): 148-150    DOI: 10.31083/j.ejgo.2020.01.4901
Case Report Previous articles | Next articles
HMGCR antibody-associated myopathy in patient with endometrial cancer: a rare case
T. Wada1, Y. Hashiguchi1, *(), M. Kasai1, T. Fukuda1, T. Ichimura1, T. Yasui1, T. Sumi1
1 Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka, Japan
Download:  PDF(5262KB)  ( 371 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Background: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibody (HMGCR antibody) antibody-associated myopathy is a rare disease. HMGCR antibody-associated myopathy in patient with endometrial cancer is extremely rare. Case Report: A 60-year-old woman without statin exposure presented with endometrial cancer Stage IIIC1 (T2N1M0) and HMGCR antibody-associated myopathy. After diagnosis, the patient received chemotherapy combining paclitaxel and carboplatin for endometrial cancer, and steroid and immunoglobulin for HMGCR antibody-associated myopathy. Two months after two cycles of chemotherapy, she died. Autopsy revealed that she died of HMGCR antibody-associated myopathy. Conclusion: In case of myopathy in patients with endometrial cancer, HMGCR antibody-associated myopathy should be considered.
Key words:  Endometrial cancer      HMGCR antibody-associated myopathy     
Published:  15 February 2020     
*Corresponding Author(s):  Y. HASHIGUCHI     E-mail:  hashiguchi@med.osaka-cu.ac.jp

Cite this article: 

T. Wada, Y. Hashiguchi, M. Kasai, T. Fukuda, T. Ichimura, T. Yasui, T. Sumi. HMGCR antibody-associated myopathy in patient with endometrial cancer: a rare case. European Journal of Gynaecological Oncology, 2020, 41(1): 148-150.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.01.4901     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I1/148

[1] Ikuji Shimazaki, Yasunori Hashiguchi, Makoto Yamauchi, Mari Kasai, Takeshi Fukuda, Tomoyuki Ichimura, Tomoyo Yasui, Toshiyuki Sumi. Secondary small cell vaginal cancer after operative therapy for endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 821-823.
[2] Yu Hui Lim, Sheow Lei Lim, Linda Xiao Hui Lin, Lay Tin Soh, Hoon Seng Khoo Tan, Richard Ming Chert Yeo, Timothy Yong Kuei Lim. Sequential Chemoradiation versus Radiation for the Adjuvant Treatment of Stage III Endometrioid Adenocarcinoma of the Uterus[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 705-712.
[3] Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.
[4] Michelle F. Benoit, Kristy K. Ward. Uterine Cancer Normogram to Predict Lymph Node Metastasis: Comparison to the Mayo Algorithm and an External Validation of a Model in a North American Population[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 681-684.
[5] Yusuf Cakmak, Tufan Oge. The effect of age on prediction of concurrent endometrial cancer in patients with atypical endometrial hyperplasia[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 531-535.
[6] Di Wu, Jirui Zhang, Chengxi Yang. Effect of letrozole combined with testosterone on the proliferation and apoptosis of endometrial carcinoma cells[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 604-608.
[7] B.-H. Zhang, L. Li, J. Ji, J. Guo, X.-L. Zhou, H. Xu, F. Cao, X.-H. Tong. Prognostic value of Foxp3+ regulatory T cells in endometrial cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 339-342.
[8] Chen J.Y., Wang Z.Q., Liang S.C., Hou H.Y., Chen D.B., Wang J.L.. Sentinel lymph node mapping with carbon nanoparticles in endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 408-414.
[9] J. Feng, J. Wu, M. Zhang, J. Wang, K. Chen, X. Li, J. Xie, J. Zhang, C. Wang. Oleic acid promotes the development of endometrial cancer by up-regulating KLF4 expression[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 432-438.
[10] S. Liu, F. Ruan, M. Shi, Y. Liu, W. Li, B. Bi, H. Wang, W. Lv. Safe fertility-preserving management in a young woman with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 476-479.
[11] K. Plagens–Rotman, M. Piskorz–Szymendera, B. PIĘTA. Lifestyle with particular emphasis on physical activity and genital carcinomas in women[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 233-239.
[12] X.Q. Wang, S.Q. Ma, J.Y. Guo, F. Zhao, X.H. Liang. Characteristics and prognostic factors among premenopausal versus postmenopausal patients with advanced endometrial cancer: a SEER-based analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 1-6.
[13] S. Srdelić Mihalj, V. Čapkun, I. Kuzmić-Prusac. High-grade endometrial cancer survival (endometrioid to non-endometrioid histology comparison)[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 16-22.
[14] Y.-S. Kwon, K. S. Im, S. B. Yoo, W. I. Kim. Two cases of uterus-conserving treatment for early stage endometrial cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 145-147.
[15] M. Englert-Golon, B. Burchardt, R. Słopień, N. Smolarek, S. Sajdak. Ovarian and endometrial cancer after breast cancer - three primary malignancies in a single patient[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 153-154.
No Suggested Reading articles found!